

REVIEW OF DECISIONS

BOARD MEETING

4-5 December 2024, Bali, Indonesia

Decision 1: Consent Agenda: Board Chair Recruitment

The Gavi Alliance Board:

Endorsed the amendments to the process for the appointment of Board Chair and in line with this amended process (Annex A to 01d), as read with Section 4.B of the Governance Committee Charter:

- a) **Delegated** to the Governance Committee the authority to set up and oversee the process for the recruitment of a Board Chair to succeed Professor José Manuel Barroso at the end of his term on 31 December 2025; and;
- b) **Delegated** to the Governance Committee the authority to establish a Search Committee for this purpose.

Decision 2: Consent Agenda: Board and Committee Appointments (1/4)

The Gavi Alliance Board:

a) **Appointed** the following Board Members:

- **Ana de Pro Gonzalo** as an Unaffiliated Board Member, effective 1 January 2025 and until 31 December 2027
- **Anna Sedgley** as an Unaffiliated Board Member, effective 1 January 2025 and until 31 December 2027
- **Alexandra Rudolph-Seemann** as Board Member representing Germany on the donor constituency cluster anchored by Germany in the seat currently held by Clarisse Paolini of France, effective 1 January 2025 and until 31 December 2025
- **Brian Erazo Muñoz** of Honduras as Board Member representing the implementing country constituency in the seat currently held by Anahit Avanesyan of Armenia, effective 1 January 2025 and until 31 December 2027

b) **Reappointed** the following Board Members:

- **Anne Schuchat** as an Unaffiliated Board Member, effective 1 January 2025 and until 31 December 2027
- **Robert Lucien Kargougou** of Burkina Faso as Board Member representing the implementing country constituency, effective 1 January 2025 and until 31 December 2027

Decision 2: Consent Agenda: Board and Committee Appointments (2/4)

c) Appointed the following Alternate Board Members:

- **Brian Erazo Muñoz** of Honduras as Alternate Board Member to Anahit Avanesyan representing the implementing country constituency, effectively immediately and until 31 December 2024
- **Frode Forland** as Alternate Board Member to Karin Berlin representing Norway on the donor constituency cluster anchored by Norway in the seat currently vacant, effective immediately and until 31 December 2025
- **Cécile Billaux** as Alternate Board Member to Alexandra Rudolph-Seemann representing the European Commission on the donor constituency cluster anchored by Germany in the seat currently held by Alexandra Rudolph-Seeman of Germany, effective 1 January 2025 and until 31 December 2025
- **Lena Nanushyan** of Armenia as Alternate Board Member to Brian Erazo Muñoz representing the implementing country constituency, effectively immediately and until 31 December 2027

d) Reappointed the following Alternate Board Members:

- **Silvia Lutucuta** of Angola as Alternate Board Member to Robert Lucien Kargougou representing the implementing country constituency, effective 1 January 2025 and until 31 December 2027

Decision 2: Consent Agenda: Board and Committee Appointments (3/4)

- e) **Reappointed** the following as Chair of the Programme and Policy Committee effective 1 January 2025:
- **Anne Schuchat** (Board Member) until 31 December 2025
- f) **Appointed** the following to the Market-Sensitive Decisions Committee effective 1 January 2025:
- **Anne Schuchat** (Board Member) until 31 December 2025
 - **Robert Lucien Kargougou** (Board Member) until 31 December 2025
 - **Cécile Billaux** (Alternate Board Member) until 31 December 2025
- g) **Appointed** the following to the Audit and Finance Committee:
- **Sara Baiocco** (Committee Delegate), effective immediately and until 31 December 2025
 - **Ana de Pro Gonzalo** (Board Member), effective 1 January 2025 and until 31 December 2025

Decision 2: Consent Agenda: Board and Committee Appointments (4/4)

i) **Appointed** the following to the Governance Committee:

- **Frode Forland** (Alternate Board Member), effective immediately and until 31 December 2025
- **Anna Sedgley** (Alternate Board Member), effective 1 January 2025 and until 31 December 2025
- **Alexandra Rudolph-Seemann** (Board Member), effective 1 January 2025 and until 31 December 2025

j) **Appointed** the following to the Programme and Policy Committee:

- **Onei Uetela** (Alternate Board Member), effective immediately and until 31 December 2025
- **Clarisse Paolini** (Committee Delegate), effective 1 January 2025 and until 31 December 2025

k) **Reappointed** the following to the Programme and Policy Committee effective 1 January 2025:

- **Brian Erazo Muñoz** (Board Member) until 31 December 2025

Decision 3: Consent Agenda: Independent Review Committee Appointments

The Gavi Alliance Board:

- a) **Appointed** as new Independent Review Committee (IRC) members the individuals listed in Annex B to Doc 01d, for a three-year term from March 2025 until March 2028; and
- b) **Approved** the extension of the IRC members listed in Annex C to Doc 01d for a further three-year term until March 2028.

Decision 4: Consent Agenda: Delegation of Authority Policy

The Gavi Alliance Board:

Approved the revised Delegation of Authority Policy attached as Annex D to Doc 01d

Decision 5: Consent Agenda: Independent Review Committee Terms of Reference

The Gavi Alliance Board:

Approved the proposed amendments to the Independent Review Committee (IRC) Terms of Reference attached as Annex E to Doc 01d

Decision 6: Consent Agenda: Waiver to Independent Review Committee Terms of Reference

The Gavi Alliance Board:

Agreed to extend the waiver of the requirement for an independent review, as outlined in the Independent Review Committee Terms of Reference, to enable Secretariat-led reviews in 2025 for i) specific low-risk requests (i.e. a subset of vaccine switches and Middle-Income Country (MIC) applications); and ii) up to ten requests for other support types (incl. new vaccine support)

Decision 7: Consent Agenda: Programme Funding Policy

The Gavi Alliance Board:

Approved the revised Programme Funding Policy as set out in Annex F to Doc 01d

Decision 8: HSIS Policy (1/4)

The Gavi Alliance Board:

1. With respect to the consolidation of funding levers:

- a) **approved** the consolidation of seven funding levers into one consolidated cash grant, namely:
 - i) Health Systems Strengthening (HSS); ii) Equity Accelerator Funding (EAF); iii) operational support for predictable campaigns; iv) Vaccine Introduction Grants (VIGs); v) predictable switch grants; vi) Innovation Top-Up; and vii) Cold Chain Equipment Optimisation Platform (CCEOP);
- b) **approved** limited guardrails to safeguard investments in Cold Chain Equipment (CCE) by introducing a minimum spending requirement for CCE based on an Alliance-validated CCE needs forecast;
- c) **approved** guardrails to safeguard investments in Civil Society Organisations (CSOs) by maintaining a 10% minimum allocation for CSOs within the consolidated grant ceilings provided to countries at the start of the strategic period;
- d) **approved** the development of a third guardrail for Measles/Measles-Rubella Follow-Up Campaigns with details to be defined in consultation with Alliance partners and outlined in the final policy document;

Decision 8: HSIS Policy (2/4)

- e) **approved** the inclusion of country-level technical assistance support into the consolidated cash envelope to countries, determined by the Health Systems and Immunisation Strengthening (HSIS) Policy allocation formula;
- f) **approved** the allocation of a portion of funding for foundational long-term country support functions, to WHO and UNICEF and, in select countries where contextually applicable, other country-selected partners. The multi-year funding shall be tied to specific results expected in country. This funding will be based on country needs, country and partner context, and defined results, to be monitored through a Board-approved accountability framework to track contributions toward results, and ensure funding reallocation as needed; and
- g) **requested** the Secretariat to present to the PPC and Board in 2025 a comprehensive plan for the evolution of the partnership model under the Partners' Engagement Framework in Gavi 6.0. The allocation proportion and methodology will be developed by the Secretariat in consultation with Countries and Alliance partners and will outline the process for identifying and funding partners for their technical assistance in country, accompanied by the above-referenced accountability framework.

Decision 8: HSIS Policy (3/4)

2. With respect to the revised allocation formula to determine Gavi's cash support in a consolidated cash grant, **approved**:
- a) a new allocation formula, that takes into account ability to pay, equity, health system performance and population size using the following indicators: GNI per capita and three-year averages of the number of children missing the first dose of diphtheria, tetanus, and pertussis vaccine (DTP1), the number of children missing the third dose (DTP3) and the number of children missing MCV2;
 - b) adjustments to the weightings of the indicators in the allocation formula to 50% for Gross National Income (GNI) per capita and 50% for performance indicators (DTP1, DTP3, MCV2), while reinstating a cap on the total amount a country can receive of health systems support and maintaining a minimum floor. Details of the caps and minimum floors will be determined following replenishment and brought back to the Board, through the PPC, for approval;
 - c) a 10% multiplier to prioritise funding for countries facing chronic fragility as defined by Gavi's Fragility, Emergencies and Displaced Population (FED) policy; and
 - d) the proposed approach to allocate funds for Measles/Measles-Rubella Follow-Up Campaigns, vaccine introductions and planned switch grants at the start of Gavi's strategic period, based on forecasts, while holding back funds for other preventive campaigns (and their associated introduction grants if relevant) until countries' applications are approved.

Decision 8: HSIS Policy (4/4)

3. In relation to programmatic sustainability, **approved** an approach to programmatic sustainability:
- a) maintaining the country joint investment requirement for cold chain equipment (CCE) and aligning with other co-financing requirements, and introducing in-kind alternatives to joint investment; and
 - b) a wide-ranging learning agenda in Gavi 6.0 to explore country specific and country-owned modalities to increase domestic investment in immunisation.

Decision 9: ELTRACO, including Catalytic Phase (1/6)

The Gavi Alliance Board, subject to the availability of funding for the 2026-2030 period following Gavi's replenishment for that period:

a) Under Shift A, **approved**:

- i. Directly linking country co-financing contribution to the price of the vaccines for specific vaccine markets for Initial Self-Financing Countries, where certain conditions are met (as outlined in Annex B to Doc 06bii);
- ii. Determining the percentage of the vaccine price that the country will pay in co-financing according to the principles of: minimal disruption to current co-financing obligations, uniform payment for the same product across Initial Self Financing (ISF) countries, and affordability of new vaccines;
- iii. Human Papillomavirus (HPV) and pneumococcal vaccine (PCV) as the first vaccine markets to meet the specific conditions under decision point a)(i), and hence the first markets for application of Shift A, with co-financing set at 4% for HPV and 7% for PCV of the vaccine price¹, in accordance with the principles of decision point a)(ii); and
- iv. Following the application of Shift A to HPV and PCV as per decision point a) (iii), that future applications of Shift A to other vaccine markets, as well as the appropriate co-financing, will be reviewed and applied by the Secretariat and approved by the Board, in accordance with the considerations and principles specified in Annex B to Doc 06bii and in decision point a)(ii), leveraging market shaping roadmap review cycles and in consultation with Alliance market shaping partners.

¹ Calculated based on current equivalence to US\$ 0.20 per dose for the highest cost product selected by countries for each vaccine

Decision 9: ELTRACO, including Catalytic Phase (2/6)

b) Under Shift B, approved:

- i. Increasing the Gavi eligibility threshold to US\$ 2,300 Gross National Income (GNI) per capita (p.c.) in 2026; and
- ii. Providing countries that regain eligibility with a downward adjustment in co-financing for individual Gavi-supported vaccine programmes, including fully self-financed ones, to 80% at the point at which they re-enter Preparatory Transition (PT) phase.

c) Under the Small Island Developing States (SIDS) Package,

- i. Approved increasing Accelerated Transition (AT) phase for SIDS to 12 years and providing a one-time downward adjustment in co-financing for individual Gavi-supported vaccine programmes, including fully self-financed ones, to 80% in 2026; and
- ii. Noted that SIDS will continue to receive programmatic support, including for campaigns, for the entirety of the AT phase.

Decision 9: ELTRACO, including Catalytic Phase (3/6)

d) Under Shift C, approved:

- i. Introducing a co-financing cap for individual Gavi-supported vaccine programmes for countries in Preparatory Transition (PT) of 80%;
- ii. Providing a downward adjustment in co-financing to individual Gavi-supported vaccine programmes, including fully self-financed ones, to 80% for countries in PT above the co-financing cap; and
- iii. For countries in PT, establishing an introductory co-financing cap of 35% for all new vaccines, with the exception of measles and measles-rubella (MR), which will remain as per the current Board decisions.

e) Under Shift D, approved:

- i. For countries in AT, establishing an introductory co-financing cap of 35% for all vaccines, with the exception of Measles and MR which will remain as per the current Board decisions; and
- ii. Providing AT countries with eight years of vaccine support for all new vaccines introduced during AT, regardless of when during the AT phase they are introduced.

Decision 9: ELTRACO, including Catalytic Phase (4/6)

f) Under Shift E, approved:

- i. Using multiple indicators measuring immunisation coverage to assess programmatic performance of AT countries, aligning directly with the indicators and levels used in the Health Systems allocation model in Gavi 6.0;
- ii. Providing five years of additional programmatic support to reinforce programmatic capacities for countries post-AT who meet the specified criteria; and
- iii. Removing the 90% coverage threshold limit for three doses of pentavalent vaccine (Penta3) for approval of new Health System Strengthening grants for countries in AT.

g) Under Shift F, approved:

- i. Allowing Gavi to provide, for countries that experience widespread, large-scale conflict or disaster of such magnitude that profoundly hampers the proper functioning of government, either (i) co-financing waivers of up to three years at any one time, or (ii) partial co-financing obligations, as per the country context.
- ii. That co-financing obligations do not apply where Gavi channels vaccines and support directly through Alliance and other partners in exceptional emergency situations and humanitarian settings.

Decision 9: ELTRACO, including Catalytic Phase (5/6)

- h) Under the Catalytic Phase², **approved**:
- i. The overall scope and eligibility for the Catalytic Phase, including vaccines in scope, as outlined in Annex C to Doc 06bii;
 - ii. Support may be channeled towards vaccine optimisation activities, including switches, to support lower middle-income countries achieve financial sustainability of their vaccine programmes. This would include support for technical assistance and one-off costs, not vaccine doses;
 - iii. Applying the proposed performance indicators and prioritisation criteria (outlined in this paper) in determining eligibility for Targeted Intervention support to Former-Gavi-eligible countries experiencing backsliding; and
 - iv. Maintaining the in-principle eligibility of both Former- and Never-Gavi eligible countries for potential Fragility Support (per June 2022 Board Decision 13).
- i) **Approved** that the new co-financing rules outlined in the above decision points can be used to inform the approval processes starting in early 2025 for implementation from 2026.

² Eligible countries are former- and never-Gavi eligible countries classified by the World Bank as lower middle-income countries (LMICs) or eligible to borrow from the International Development Association (IDA)

Decision 9: ELTRACO, including Catalytic Phase (6/6)

- j) **Approved** the application of decision points (d)(iii), (e)(i) and (e)(ii) in 2025 in situations where countries are ready to introduce vaccines, to avoid delaying such introductions, with an additional estimated financial implication of US\$ 9.5 million (US\$ 0.5 million in 2025 and US\$ 9 million in Gavi 6.0);
- k) **Approved** that for currently eligible Gavi countries expected to benefit from decision points (b)(ii) and (c)(i) in 2026, the co-financing shared are held constant at 2024 levels in 2025 for any individual Gavi-supported vaccine programme with a co-financing share at or above 80%, at an additional estimated cost of US\$ 3.9 million in 2025; and
- l) **Requested** that the Secretariat put forward options for addressing the pace of change in co-financing for PT countries. This will be part of a series of other potential investments to be explored by the Board in 2025 as part of further prioritisation of programmes when future resources and other Gavi cost areas are more clear.

Decision 10: Treasury Management of AVMA and FRF

The Gavi Alliance Board:

- a) **Approved** the World Bank Reserve Advisory & Management Partnership as the treasury manager for the African Vaccine Manufacturer Accelerator (AVMA);
- b) **Approved** the World Bank Reserve Advisory & Management Partnership as the treasury manager for the First Response Fund (FRF);
- c) **Approved** the extension of the Gavi Secretariat serving as the interim treasury manager for AVMA and FRF until, in each case, the long-term arrangement is operational; and
- d) **Noted** specific investment strategies for AVMA and FRF will be reviewed and approved by the Investment Committee.

Decision 11: Financial Update (1/2)

The Gavi Alliance Board:

- a) **Approved** the updated Financial Forecast for the Gavi 5.1 (2021-2025) Strategic Period of Qualifying Resources of US\$ 10.8 billion and Forecast Expenditure of US\$ 10.7 billion;
- b) **Approved** the updated Financial Forecast for the COVAX AMC and ongoing Board-approved programmes of Qualifying Resources of US\$ 13.2 billion and Forecast Expenditure of US\$ 11.5 billion, with a COVAX AMC retained balance of US\$ 1.6 billion;
- c) **Noted** US\$ 199 million of future COVAX AMC interest and US\$ 318 million of earned interest (subject to expected completion of COVAX AMC donor repurposing agreement) are included in the forecast and are made available for Gavi 5.1 Board approved programmes and (ii) the planned market shaping firm order commitment to be presented to the Market-Sensitive Decisions Committee in due course has been reflected in the financial forecast and can be funded from the forecast resources available;

Decision 11: Financial Update (2/2)

- d) **Noted** that the Board has approved up to US\$ 1 billion for the African Vaccine Manufacturing Accelerator (AVMA) and a further US\$ 176 million has been reallocated by donors; the Board has approved up to US\$ 22 million for the Pandemic Prevention, Preparedness and Response (PPPR) Coalition and a further US\$ 3 million has been reallocated by donors. The Secretariat will not commit above the current Board-approved envelopes until the Board approves the additional programming;
- e) **Noted** that the Board has approved up to US\$ 500 million for Day Zero First Response Fund and a further US\$ 49 million has been reallocated by donors; the Board has approved up to US\$ 290 million for the Big Catch Up and a further US\$ 8 million has been reallocated by donors. The Secretariat will not commit above the current Board-approved envelopes until the Board approves the additional programming;
- f) **Noted** that the Financial Forecast reflects a detailed review of programme expenditures, cash balances in country and other sources of funding to ensure that resources that could be used in Gavi 6.0 and are being used in Gavi 5.1 are necessary to meet higher demand; and
- g) **Noted** that there are no financial implications to consider in this updated financial forecast for the Gavi 5.1 strategic period arising from the recommendations being asked of the Programme and Policy Committee.

Decision 12: Financial Update

The Gavi Alliance Board:

- a) **Approved** US\$ 199 million for the Secretariat Operating budget in 2025, noting that the Gavi Secretariat will present an approach to the Gavi Alliance Board in December 2024 setting out how it will ensure the Gavi Secretariat is fit for purpose for the Gavi 6.0 strategic period;
- b) **Approved** US\$ 1 million for Capital Expenditure budget in 2025;
- c) **Approved** US\$ 8.4 million carry forward of the Partners' Engagement Framework budget from 2023 to 2024; and
- d) **Approved** US\$ 114.3 million for the Partners' Engagement Framework budget in 2025.

Decision 13: Prioritisation Mechanism

The Gavi Alliance Board:

- a) **Approved** the revised update of the ‘Prioritisation Mechanism for Gavi’s Support to Countries’ attached as Annex A to Doc 10; and
- b) **Noted** that the Secretariat will propose further revisions to the Mechanism during 2025 to ensure that it is fit for purpose for the Gavi 6.0 strategic period.

Decision 14: Risk

The Gavi Alliance Board:

- a) **Approved** the Annual Risk & Assurance Report 2024 attached as Annex A to Doc 11; and
- b) **Approved** the updated Risk Policy attached as Annex B to Doc 11.

Thank you